한국형 양극성 장애 약물치료 알고리듬 2022: 동반 신체질환

키워드

참고문헌 (29)

1. Akiskal HS, "Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders", J Affect Disord, 59(Suppl 1), pp.S5~S30 (2000)
2. Beyer J, "Medical comorbidity in a bipolar outpatient clinical population", Neuropsychopharmacology, 30, pp.401~404 (2005)
3. Carney CP, "Medical comorbidity in women and men with bipolar disorders : a population-based controlled study", Psychosom Med, 68, pp.684~691 (2006)
4. 전덕인, "양극성 장애 환자의 의학적 공존질환：후향적 챠트 조사", Mood and Emotion, 5(1), pp.30~33 (2007), 대한우울조울병학회
5. 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
6. 윤보현, "한국형 양극성 장애 약물치료 알고리듬 2010: 다른 치료 지침들과의 비교", 대한정신약물학회지, 22(4), pp.171~182 (2011), 대한정신약물학회
7. 송후림, "한국형 양극성 장애 약물치료 알고리듬 2018 : 신체 질환이 동반되었을 경우", Mood and Emotion, 16(3), pp.129~133 (2018), 대한우울조울병학회
8. Salvador-Carulla L, "From the EBM pyramid to the Greek temple : a new conceptual approach to guidelines as implementation tools in mental health", Epidemiol Psychiatr Sci, 26, pp.105~114 (2017)
9. Hohmann E, "Expert opinion is necessary : Delphi panel methodology facilitates a scientific approach to consensus", Arthroscopy, 34, pp.349~351 (2018)
10. Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision", Clinical Psychopharmacology and Neuroscience, 16(4), pp.434~448 (2018), 대한정신약물학회[DOI]
11. Carli M, "Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences", Pharmaceuticals (Basel), 14, pp.238~ (2021)
12. Reynolds GP, "Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment", J Psychopharmacol, 31, pp.1430~1436 (2017)
13. Argo TR, "Aripiprazole, a novel atypical antipsychotic drug", Pharmacotherapy, 24, pp.212~228 (2004)
14. Camm AJ, "Ziprasidone and the corrected QT interval : a comprehensive summary of clinical data", CNS Drugs, 26, pp.351~365 (2012)
15. Baptista T, "Drug induced weight gain, an impediment to successful pharmacotherapy:focus on antipsychotics", Curr Drug Targets, 5, pp.279~299 (2004)
16. Hasnain M, "Weight considerations in psychotropic drug prescribing and switching", Postgrad Med, 125, pp.117~129 (2013)
17. Yatham LN, "Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
18. McGirr A, "Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials", Lancet Psychiatry, 3, pp.1138~1146 (2016)
19. Miura T, "Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis", Lancet Psychiatry, 1, pp.351~359 (2014)
20. Baldessarini RJ, "Bipolar depression : a major unsolved challenge", Int J Bipolar Disord, 8, pp.1~ (2020)
21. Levy RH, "Antiepileptic drugs", pp.605~620 (1995), Raven Press
22. Hayes JF, "Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a populationbased cohort study", PLoS Med, 13, pp.e1002058~ (2016)
23. Bhagwagar Z, "Lamotrigine in the treatment of bipolar disorder", Expert Opin Pharmacother, 6, pp.1401~1408 (2005)
24. Wootton R, "Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers", Br J Clin Pharmacol, 43, pp.23~27 (1997)
25. Telles-Correia D, "Psychotropic drugs and liver disease : a critical review of pharmacokinetics and liver toxicity", World J Gastrointest Pharmacol Ther, 8, pp.26~38 (2017)
26. Robert S, "Traumatic brain injury and mood disorders", Ment Health Clin, 10, pp.335~345 (2020)
27. Goodwin GM, "Evidence-based guidelines for treating bipolar disorder:revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30, pp.495~553 (2016)
28. Fountoulakis KN, "The International College of Neuro-Psychopharmacology (CINP)treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines", Int J Neuropsychopharmacol, 20, pp.180~195 (2017)
29. Greger J, "Comparison of the metabolic characteristics of newer second generation antipsychotics: brexpiprazole, lurasidone, asenapine, cariprazine, and iloperidone with olanzapine as a comparator", J Clin Psychopharmacol, 41, pp.5~12 (2021)

관련 논문AI추천